Journal
BRITISH JOURNAL OF CANCER
Volume 97, Issue 2, Pages 145-151Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6603860
Keywords
gemcitabine; pharmacogenomics; polymorphisms; gene expression; tailor-made therapy
Categories
Ask authors/readers for more resources
Gemcitabine is a deoxycytidine analogue that has a broad spectrum of antitumour activity in many solid tumours including pancreatic cancer. We have recently carried out a pharmacogenomic study in cancer patients treated with gemcitabine, and found that one genetic polymorphism of an enzyme involved in gemcitabine metabolism can cause interindividual variations in the pharmacokinetics and toxicity of this agent. In this paper, we review recent genetic studies of gemcitabine, and discuss the possibility of individualised cancer chemotherapy based on a pharmacogenomic approach.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available